What Is Semax? A Complete Scientific Guide

Semax is a synthetic peptide developed for research into brain function, cognitive performance and neurological injury.

It is frequently described as a:

• Nootropic

• Neuroprotective peptide

• Neurotrophic peptide

• Cognitive enhancer

These descriptions are largely based on laboratory experiments, animal studies and a comparatively small body of human research conducted primarily in Russia.

Semax was developed from a short fragment of adrenocorticotropic hormone, commonly abbreviated to ACTH.

However, Semax does not reproduce all the hormonal actions of full-length ACTH.

Instead, researchers modified a shorter ACTH fragment in an attempt to retain potential nervous-system effects while reducing activity associated with adrenal hormone production.

Experimental research suggests Semax may influence:

• Brain-derived neurotrophic factor

• Nerve growth factor

• Dopamine signalling

• Serotonin signalling

• Gene expression

• Inflammatory pathways

• Oxidative stress

• Cerebral blood-flow responses

• Learning and memory

Small clinical studies have investigated Semax in areas including:

• Ischaemic stroke

• Cognitive impairment

• Optic-nerve disorders

• Attention and memory

• Recovery after neurological injury

Although some findings are encouraging, the evidence base remains limited by small study sizes, older trial designs, limited independent replication and a concentration of research within a relatively small scientific network.

Semax has not been established through large multinational trials as a general treatment for cognitive decline, stroke, dementia, attention disorders or brain injury.

This guide examines what Semax is, how it was developed, its proposed mechanisms, the available human evidence and the substantial uncertainties that remain.

Semax quick facts

Semax contains the first four amino acids of the ACTH 4–7 sequence followed by a Pro-Gly-Pro tripeptide intended to increase stability.

What is Semax?

Semax is a synthetic peptide containing seven amino acids.

Its sequence is:

Met-Glu-His-Phe-Pro-Gly-Pro

This is commonly abbreviated to:

MEHFPGP

The first four amino acids are derived from positions 4–7 of ACTH:

Met-Glu-His-Phe

A three-amino-acid sequence was then added:

Pro-Gly-Pro

This modification was designed to increase resistance to enzymatic degradation and prolong biological activity.

Semax is therefore commonly described chemically as:

ACTH(4–7)-Pro-Gly-Pro

or:

ACTH(4–7)PGP

It is not full-length ACTH and should not be assumed to produce the same endocrine effects.

What is ACTH?

Adrenocorticotropic hormone is a peptide hormone produced by the anterior pituitary gland.

Its principal endocrine role is stimulating the adrenal cortex to produce hormones including cortisol.

Full-length ACTH contains 39 amino acids.

Different sections of the ACTH molecule may have different biological properties.

Semax was developed from a short N-terminal ACTH fragment rather than the complete hormone.

Researchers were interested in evidence suggesting that some ACTH fragments could influence:

• Learning

• Memory

• Motivation

• Nervous-system adaptation

• Stress responses

without necessarily producing the full adrenal effects of ACTH.

Does Semax increase cortisol?

Semax is not equivalent to full-length ACTH.

The short ACTH-derived sequence used in Semax was selected partly because it was believed to retain neuroactive properties without strongly stimulating the adrenal cortex.

However, this does not mean that all endocrine interactions have been conclusively excluded in every population or at every exposure level.

There is insufficient large-scale human evidence to describe Semax as having no possible influence on the hypothalamic-pituitary-adrenal system.

It should not be used as a substitute for investigating abnormal cortisol or adrenal function.

How was Semax developed?

Semax was developed by researchers associated with the Institute of Molecular Genetics of the Russian Academy of Sciences.

Its development formed part of broader research into short regulatory peptides derived from naturally occurring hormones.

The aim was to create a compound with potential:

• Neuroprotective activity

• Cognitive effects

• Resistance to enzymatic degradation

• Intranasal activity

• Reduced peripheral hormonal action

The resulting heptapeptide was investigated in laboratory models of:

• Cerebral ischaemia

• Hypoxia

• Memory impairment

• Stress

• Neuroinflammation

• Optic-nerve injury

Human studies later examined its possible use in neurological and cognitive disorders.

What does neuroprotective mean?

A neuroprotective compound is one that may reduce damage to nerve cells or help preserve neurological function during harmful conditions.

Examples of harmful conditions include:

• Oxygen deprivation

• Reduced blood flow

• Inflammation

• Oxidative stress

• Excitotoxicity

• Traumatic injury

The term does not automatically mean that a substance prevents neurological disease in humans.

Many compounds appear neuroprotective in cell cultures or animal models but fail to produce meaningful benefits in clinical trials.

For Semax, much of the neuroprotective evidence remains preclinical.

Is Semax a nootropic?

Semax is often described as a nootropic because research has investigated possible effects on:

• Learning

• Memory

• Attention

• Executive function

• Cognitive recovery after neurological injury

Some animal and human studies have reported cognitive effects following intranasal administration. A scientific review described findings involving memory and attention, while also discussing proposed effects on dopamine and BDNF pathways.

However, the term nootropic is broad and is often used commercially without a consistent scientific definition.

Evidence that a compound influences memory after stroke or experimental brain injury does not establish that it improves intelligence or mental performance in healthy people.

How does Semax work?

Semax does not have one conclusively identified primary receptor.

Its proposed effects appear to involve several overlapping biological systems.

These include:

• Neurotrophin signalling

• Dopamine transmission

• Serotonin transmission

• Gene expression

• Inflammatory signalling

• Oxidative-stress responses

• Mitochondrial stability

• Nitric-oxide pathways

• Melanocortin-related signalling

Researchers have also proposed that metabolites produced when Semax is broken down may contribute to its biological effects.

Because multiple pathways change after administration, it remains difficult to determine which mechanism is primarily responsible for any observed clinical effect.

Semax and BDNF

One of the best-known proposed mechanisms involves brain-derived neurotrophic factor, or BDNF.

BDNF is a protein involved in:

• Neuronal survival

• Synaptic plasticity

• Learning

• Memory

• Formation of neural connections

• Adaptation after injury

Animal research has reported increased BDNF expression after intranasal Semax administration.

One study found that Semax influenced BDNF levels and signalling in the rat basal forebrain.

Other experimental work has reported changes in BDNF, its receptor TrkB and nerve growth factor pathways.

These results are biologically interesting, but they do not prove that Semax prevents dementia, permanently increases brain function or produces meaningful cognitive enhancement in healthy humans.

What is BDNF?

Brain-derived neurotrophic factor is part of the neurotrophin family.

It contributes to:

• Growth of developing neurons

• Survival of existing neurons

• Synaptic communication

• Learning-related plasticity

• Memory formation

BDNF concentrations and activity are influenced by many factors, including:

• Exercise

• Sleep

• Stress

• Age

• Metabolic health

• Neurological disease

Increasing one BDNF measurement does not necessarily produce a clinically beneficial outcome.

The location, timing and duration of the change are all important.

Semax and nerve growth factor

Nerve growth factor, or NGF, is another neurotrophin involved in the development and maintenance of nerve cells.

Experimental studies have reported altered NGF-related gene expression after Semax exposure.

Research in rat brain tissue and glial cells suggests Semax may stimulate both BDNF- and NGF-associated pathways.

The significance of these findings for human neurological disease remains uncertain.

Semax and dopamine

Dopamine is a neurotransmitter involved in:

• Motivation

• Reward

• Movement

• Attention

• Learning

• Reinforcement

Preclinical work suggests Semax may modify dopamine release or dopamine-related signalling.

A review of Semax research reported that it could augment psychostimulant-associated dopamine release in experimental models.

This does not establish Semax as a treatment for:

• ADHD

• Parkinson’s disease

• Depression

• Low motivation

• Substance-use disorders

Dopamine systems are complex, and increasing dopamine activity is not automatically beneficial.

Semax and serotonin

Serotonin contributes to:

• Mood

• Anxiety

• Sleep

• Appetite

• Pain processing

• Gastrointestinal function

Animal research has suggested that Semax may influence serotonergic signalling within the striatum.

One study reported a modulatory effect on serotonin release and metabolism in rat brain tissue.

These findings have not established Semax as an antidepressant or anxiety treatment in humans.

Semax and gene expression

Semax has been studied using transcriptomic and gene-expression methods.

Researchers have reported changes involving genes associated with:

• Inflammation

• Neurotransmission

• Neurotrophic signalling

• Vascular function

• Immune responses

• Cell survival

• Oxidative stress

In rodent models of cerebral ischaemia, Semax was associated with changes in gene-expression patterns disturbed by reduced brain blood flow.

These studies help identify possible mechanisms.

However, a change in gene expression does not automatically demonstrate:

• Clinical effectiveness

• Permanent neurological recovery

• Improved cognition

• Long-term safety

Gene-expression findings must be interpreted alongside functional and clinical outcomes.

Semax and cerebral ischaemia

Cerebral ischaemia occurs when blood flow to part of the brain is reduced or blocked.

This deprives neurons of:

• Oxygen

• Glucose

• Nutrients

Within minutes, a cascade of injury can begin involving:

• Energy failure

• Excitotoxicity

• Oxidative stress

• Inflammation

• Cell death

• Blood-brain barrier disruption

Semax has been extensively investigated in animal models of cerebral ischaemia.

Reported findings include:

• Reduced neurological damage

• Improved behavioural recovery

• Changes in inflammatory gene expression

• Increased neurotrophic signalling

• Improved performance in learning tasks

Modern reviews describe substantial preclinical evidence, but also make clear that the mechanisms remain under investigation.

Semax and stroke

Stroke has been one of the main clinical research areas for Semax.

Several older Russian studies examined its addition to conventional treatment following acute ischaemic stroke.

One study involved 30 patients treated during the acute phase of hemispheric ischaemic stroke and compared outcomes with a larger conventionally treated control group.

Another publication described clinical and immunobiochemical research into Semax during acute ischaemic stroke.

These studies reported favourable findings, but they have significant limitations when judged against modern evidence standards.

Potential limitations include:

• Small treatment groups

• Non-randomised comparisons

• Limited blinding

• Older standards of stroke treatment

• Incomplete reporting

• Limited independent international replication

Semax has not become part of standard UK stroke treatment.

Suspected stroke is a medical emergency requiring immediate evidence-based care.

Can Semax reverse a stroke?

No evidence establishes that Semax can reverse an established stroke.

The most effective stroke treatments depend on:

• Rapid recognition

• Brain imaging

• Stroke type

• Time since symptom onset

• Thrombolysis eligibility

• Mechanical thrombectomy eligibility

• Specialist stroke-unit care

Experimental neuroprotection should never delay emergency treatment.

Semax should not be presented as a substitute for thrombolysis, thrombectomy, antiplatelet therapy, rehabilitation or other established stroke care.

Semax and stroke recovery

Some research suggests Semax may influence neurological recovery after ischaemic injury.

Possible mechanisms include:

• Neurotrophin activation

• Reduced inflammatory signalling

• Support of neuronal survival

• Changes in synaptic plasticity

However, neurological recovery depends on many factors:

• Size and location of the stroke

• Speed of treatment

• Age

• General health

• Rehabilitation

• Secondary complications

The available evidence is not strong enough to establish Semax as a routine stroke-rehabilitation medicine internationally.

Semax and hypoxia

Hypoxia means reduced oxygen availability.

Neurons are particularly vulnerable to oxygen deprivation because the brain has high energy demands and limited energy storage.

Laboratory and animal studies suggest Semax may influence cellular responses to hypoxia.

Reported mechanisms include:

• Mitochondrial stabilisation

• Neurotrophic signalling

• Oxidative-stress regulation

• Reduced inflammatory activity

These findings remain predominantly preclinical.

Semax and oxidative stress

Oxidative stress occurs when the production of reactive oxygen species exceeds the ability of antioxidant systems to control them.

Excess oxidative stress can damage:

• DNA

• Proteins

• Cell membranes

• Mitochondria

It plays a role in many neurological disorders but is not the sole cause of any one disease.

Semax has demonstrated antioxidant- and stress-related effects in some experimental models.

This does not establish it as a proven antioxidant therapy in humans.

Semax and inflammation

Inflammation is an important part of the brain’s response to injury.

After ischaemic stroke, immune signalling can contribute both to:

• Removal of damaged tissue

• Secondary neuronal injury

Animal studies suggest Semax may modify inflammatory gene-expression patterns following cerebral ischaemia.

The aim of neuroprotective treatment is not necessarily to eliminate inflammation completely, because some inflammatory processes support repair.

The clinical significance of Semax’s reported anti-inflammatory effects remains uncertain.

Semax and mitochondria

Mitochondria generate most cellular ATP.

Brain cells rely heavily on mitochondrial energy because neuronal signalling requires substantial and continuous ATP production.

Experimental literature suggests Semax may help stabilise mitochondrial function during certain forms of cellular stress.

It has not been proven to repair all forms of mitochondrial dysfunction or treat inherited mitochondrial disease.

Semax and nitric oxide

Nitric oxide is a signalling molecule involved in:

• Blood-vessel relaxation

• Cerebral circulation

• Immune signalling

• Neurotransmission

• Oxidative stress

Semax has been reported to influence nitric-oxide-related pathways in experimental research.

Nitric oxide can have both protective and harmful effects depending on:

• Concentration

• Cellular source

• Timing

• Disease state

It is therefore inaccurate to describe nitric oxide as universally beneficial or harmful.

Semax and memory

Memory is one of the most widely promoted applications of Semax.

Animal studies have investigated:

• Passive-avoidance learning

• Food-motivated learning

• Spatial memory

• Stress-induced memory impairment

• Memory after cerebral ischaemia

Several studies have reported improved performance under specific experimental conditions.

A review of ACTH-derived peptides described Semax as facilitating certain learning tasks and reducing memory impairment in animal models.

These findings do not establish that Semax reliably improves everyday memory in healthy humans.

Semax and learning

Learning in animal experiments is often measured through tasks such as:

• Maze navigation

• Avoidance behaviour

• Conditioned responses

• Reward-based tasks

These are useful scientific tools but do not directly reproduce:

• Academic learning

• Professional decision-making

• Language learning

• Human creativity

• General intelligence

A positive result in a rodent learning test is a starting point for research, not proof of human cognitive enhancement.

Semax and attention

Some publications report that Semax may influence selective attention.

The available research includes experimental and small human studies, but it does not establish Semax as an approved treatment for attention disorders.

Attention is influenced by:

• Sleep

• Anxiety

• Depression

• Medication

• Motivation

• ADHD

• Stress

• Physical health

Improved performance on one attention test does not necessarily translate into broad everyday cognitive improvement.

Semax and ADHD

Semax is sometimes promoted online for attention-deficit hyperactivity disorder.

There is insufficient high-quality evidence to establish it as a treatment for ADHD.

Established ADHD treatments have undergone extensive controlled research examining:

• Symptom reduction

• Functional improvement

• Long-term outcomes

• Adverse effects

• Dosing

• Interactions

Semax has not accumulated an equivalent evidence base.

Semax and healthy cognition

A small functional MRI study examined changes in the brain’s default mode network after intranasal Semax in healthy volunteers.

The study included 24 participants, with scans performed before and shortly after Semax or placebo administration.

Another study examined whole-brain functional connectivity after Semax and Selank in 52 healthy participants.

Brain-imaging changes are not equivalent to proven improvements in:

• Memory

• Intelligence

• Productivity

• Mental health

• Long-term brain health

Imaging findings are exploratory and require replication alongside meaningful cognitive outcomes.

What is the default mode network?

The default mode network is a group of brain regions that show coordinated activity during internally focused mental states.

It is associated with processes such as:

• Self-referential thought

• Autobiographical memory

• Mind wandering

• Future planning

Changes in default mode network connectivity occur in many circumstances.

A measurable connectivity change is not automatically beneficial or harmful.

Semax and executive function

Executive function includes:

• Planning

• Working memory

• Inhibition

• Flexible thinking

• Decision-making

Some functional-connectivity research has examined brain regions associated with executive control after Semax administration.

Evidence remains insufficient to conclude that Semax reliably improves executive function in healthy adults.

Semax and dementia

Semax has been discussed as a potential neuroprotective compound in relation to age-related neurological disease.

However, it has not been proven to prevent or treat:

• Alzheimer’s disease

• Vascular dementia

• Lewy body dementia

• Frontotemporal dementia

Laboratory findings involving BDNF, inflammation or oxidative stress are not equivalent to demonstrating slower cognitive decline in patients.

Recent experimental work continues to explore Semax and modified derivatives for Alzheimer’s-related mechanisms, but this remains investigational.

Semax and Parkinson’s disease

Dopamine-related findings have led to interest in possible applications involving Parkinson’s disease.

Parkinson’s disease involves progressive loss of dopamine-producing neurons and multiple non-dopaminergic systems.

There is insufficient clinical evidence to establish Semax as a treatment for Parkinson’s disease.

It should not replace established neurological care.

Semax and traumatic brain injury

Traumatic brain injury may involve:

• Direct tissue damage

• Inflammation

• Bleeding

• Axonal injury

• Excitotoxicity

• Mitochondrial dysfunction

Semax is sometimes promoted for concussion or traumatic brain injury because of its preclinical neuroprotective profile.

Robust human trials demonstrating improved recovery after traumatic brain injury are lacking.

Concussion symptoms require proper assessment, particularly when accompanied by:

• Loss of consciousness

• Repeated vomiting

• Worsening headache

• Confusion

• Weakness

• Seizure

• Unequal pupils

Semax and spinal-cord injury

Recent animal research has examined ACTH-derived peptides in models of spinal-cord injury.

A 2025 experimental study investigated possible anti-inflammatory and neuroprotective effects of Semax in this context.

This remains preclinical research and does not demonstrate that Semax restores spinal-cord function in humans.

Semax and optic-nerve research

Semax has also been investigated in relation to optic-nerve and retinal disorders.

The proposed rationale includes:

• Neurotrophic signalling

• Vascular effects

• Reduced oxidative damage

• Neuronal survival

The evidence base is not sufficient to establish Semax as an internationally accepted treatment for optic neuropathy, glaucoma or retinal disease.

Sudden visual loss is a medical emergency and should not be self-treated.

Semax and stress

Semax is derived from an ACTH fragment, and ACTH is closely related to the physiological stress response.

Animal studies suggest Semax and related melanocortin fragments may alter behavioural responses to acute and chronic stress.

Reported findings include reduced stress-associated cognitive impairment in rodents.

These results do not establish Semax as a treatment for chronic stress, anxiety disorders or post-traumatic stress disorder.

Semax and anxiety

Semax is less directly associated with anxiety research than Selank.

Some preclinical findings suggest it may influence stress-related behaviour, but the human evidence is insufficient to classify it as an established anxiolytic.

Selank was developed more specifically around anxiety-related applications, while Semax has been researched more heavily in cognition and neuroprotection.

Neither is an authorised UK anxiety medicine.

Semax and depression

Neurotrophins, dopamine and serotonin are all relevant to depression research.

This has led to speculation that Semax might have antidepressant effects.

However, there is insufficient robust clinical evidence demonstrating that Semax treats major depressive disorder.

Depression is a complex medical condition involving biological, psychological and social factors.

Experimental peptide use should not replace appropriate mental-health treatment.

Semax and motivation

Because dopamine contributes to motivation and reward, Semax is sometimes described as a motivation enhancer.

This claim remains unproven.

Motivation can be reduced by:

• Depression

• Sleep deprivation

• Anxiety

• Burnout

• Chronic illness

• Medication effects

• Nutritional deficiencies

• ADHD

A compound influencing dopamine in animal experiments does not automatically improve healthy human motivation.

Semax and physical performance

There is no strong evidence establishing Semax as a physical-performance enhancer.

Any proposed effects would likely be indirect and could involve:

• Attention

• Stress tolerance

• Perceived fatigue

• Motor learning

These possibilities have not been adequately demonstrated through controlled athletic-performance trials.

How is Semax administered in research?

Semax has commonly been investigated through intranasal administration.

The nasal route may offer several theoretical advantages:

• Rapid absorption

• Avoidance of gastrointestinal digestion

• Access to highly vascular nasal tissue

• Possible nose-to-brain transport pathways

However, intranasal delivery does not guarantee that intact Semax reaches the brain in large or predictable amounts.

Absorption may vary according to:

• Formulation

• Nasal inflammation

• Spray technique

• Mucus clearance

• Enzymatic degradation

• Product concentration

Can Semax cross the blood-brain barrier?

The precise human brain exposure following intranasal administration has not been fully characterised.

Possible routes of action include:

• Direct nose-to-brain transport

• Systemic absorption followed by brain entry

• Peripheral signalling

• Active metabolites

• Sensory-nerve pathways

Central nervous-system effects do not prove that a large proportion of intact Semax crosses the blood-brain barrier.

Semax metabolites

Semax is broken down by peptidase enzymes into shorter fragments.

The Pro-Gly-Pro sequence and related fragments may have biological activity of their own.

This has led researchers to propose that Semax may act as a parent peptide that produces multiple active metabolites.

The importance of each metabolite in humans remains uncertain.

Semax and Pro-Gly-Pro

Pro-Gly-Pro is the three-amino-acid sequence added to the ACTH-derived portion of Semax.

It was intended partly to improve stability.

Experimental research suggests Pro-Gly-Pro may also influence some of the same gene-expression pathways as Semax.

The complete contribution of the PGP sequence to Semax’s effects remains under investigation.

What is the half-life of Semax?

Comprehensive human pharmacokinetic data remain limited.

A precise universal half-life should therefore be treated cautiously.

Peptides may disappear from blood relatively quickly while producing signalling changes that persist longer.

The duration of a biological response is not necessarily the same as the time the intact peptide remains measurable.

How quickly does Semax work?

There is no universally established onset time.

Small imaging studies have detected brain-connectivity changes within minutes of intranasal administration.

This does not prove that clinically meaningful cognitive effects occur within the same period.

Onset may differ according to:

• Outcome measured

• Route

• Formulation

• Individual biology

• Health condition

Human clinical evidence

The human Semax literature includes studies involving:

• Acute ischaemic stroke

• Cognitive performance

• Attention

• Functional brain imaging

• Cerebrovascular disorders

• Optic-nerve conditions

The evidence is more substantial than for some research peptides but far weaker than the evidence supporting internationally approved neurological medicines.

Major limitations include:

• Small participant groups

• Older studies

• Limited randomisation

• Limited placebo control

• Research concentrated in one region

• Incomplete long-term follow-up

• Limited independent replication

• Differences from modern treatment standards

Positive findings should therefore be viewed as preliminary rather than definitive.

Is Semax approved?

Semax has been described in scientific literature as a peptide medicine developed and used in Russia.

However, it is not an authorised medicine in the United Kingdom.

It has not received approval from the MHRA for treating:

• Stroke

• Dementia

• Cognitive impairment

• ADHD

• Depression

• Traumatic brain injury

• General cognitive enhancement

Regulatory recognition in one jurisdiction does not automatically establish approval, legal status or accepted medical use elsewhere.

Semax vs Selank

Semax and Selank are frequently discussed together, but they are different compounds.

Semax has been studied more heavily in:

• Cerebral ischaemia

• Memory

• Attention

• Neurotrophic signalling

Selank has been studied more heavily in:

• Anxiety

• Stress

• GABA-related signalling

• Enkephalin metabolism

They should not be treated as interchangeable.

Semax vs ACTH

Semax contains only a small ACTH-derived sequence.

Full ACTH:

• Contains 39 amino acids.

• Stimulates adrenal cortisol production.

• Has recognised diagnostic and therapeutic uses.

Semax:

• Contains seven amino acids.

• Was designed around a short ACTH neuroactive fragment.

• Is investigated mainly for central nervous-system effects.

• Does not have the established endocrine profile of full ACTH.

Evidence involving ACTH cannot automatically be applied to Semax.

Semax vs cerebrolysin

Cerebrolysin is a mixture of peptides and amino acids derived from porcine brain proteins.

Semax is a single defined synthetic heptapeptide.

Although both are discussed in neuroprotection research, they differ substantially in:

• Composition

• Manufacturing

• Mechanism

• Clinical evidence

• Regulatory status

Studies involving one cannot be used as proof for the other.

Safety and adverse effects

Published Semax studies generally describe short-term tolerability as acceptable.

However, the total safety database remains limited.

Potential concerns include:

• Nasal irritation

• Headache

• Dizziness

• Fatigue

• Changes in mood or alertness

• Allergic reactions

• Unknown medicine interactions

• Product contamination

• Incorrect concentration

Small trials are unlikely to detect rare adverse effects.

Long-term safety in healthy users has not been established.

Nasal adverse effects

Intranasal products may cause:

• Burning

• Dryness

• Irritation

• Sneezing

• Congestion

• Nosebleeds

Repeated exposure may be affected by preservatives, pH and formulation quality.

A product intended for laboratory research may not have been assessed for repeated use on human nasal tissue.

Psychiatric considerations

Substances that influence dopamine, serotonin or neurotrophic signalling may produce different effects in different individuals.

Particular caution is warranted in people with:

• Bipolar disorder

• Psychosis

• Severe anxiety

• Major depression

• Substance-use disorders

• Complex psychiatric medication regimens

Unexpected changes in mood, sleep, behaviour or perception require medical assessment.

Semax and antidepressants

There is insufficient controlled evidence to establish the safety of combining Semax with:

• SSRIs

• SNRIs

• Tricyclic antidepressants

• MAO inhibitors

• Atypical antidepressants

Potential interactions remain uncertain because Semax may influence serotonergic and dopaminergic systems.

Absence of a documented interaction is not proof of safety.

Semax and stimulant medication

Preclinical evidence suggests Semax may alter psychostimulant-related dopamine release.

This raises theoretical questions about combining it with stimulant medicines.

Controlled human interaction studies are lacking.

Possible concerns could include:

• Anxiety

• Insomnia

• Elevated heart rate

• Mood changes

• Excessive stimulation

Semax and alcohol

There is insufficient evidence to define the interaction between Semax and alcohol.

Combining experimental neuroactive compounds with alcohol may produce unpredictable effects on:

• Judgement

• Coordination

• Mood

• Alertness

• Sleep

Pregnancy and breastfeeding

Adequate reproductive and developmental safety data are lacking.

Semax cannot be considered established as safe during:

• Pregnancy

• Breastfeeding

• Fertility treatment

Peptides affecting neurological or hormonal signalling could theoretically influence fetal or infant development.

Children and adolescents

Semax has been discussed in relation to paediatric neurological and attention disorders in some regional literature.

However, large modern safety trials in children and adolescents are lacking.

Developing nervous systems may respond differently from adult brains.

Cancer considerations

Semax has not been established as a carcinogen.

However, its proposed influence on:

• Neurotrophic factors

• Cell-survival pathways

• Angiogenesis-related signalling

• Gene expression

creates theoretical questions that require long-term study.

BDNF and other growth-related pathways can have different effects depending on tissue and disease context.

There is insufficient evidence to determine the safety of Semax in people with active cancer.

Product-quality concerns

Commercially available Semax may not be identical to the compound used in published studies.

Important quality factors include:

• Correct amino-acid sequence

• Molecular identity

• Purity

• Concentration

• Sterility

• Endotoxin levels

• Nasal formulation

• pH

• Preservatives

• Storage

• Degradation

A stated purity percentage does not establish that a product is sterile, accurately concentrated or suitable for human use.

Analytical testing

High-performance liquid chromatography

HPLC can estimate purity and separate some impurities.

It does not prove sterility or confirm every aspect of identity.

Mass spectrometry

Mass spectrometry can help confirm molecular mass.

It is commonly used alongside chromatographic testing.

Microbiological testing

This helps detect bacterial or fungal contamination.

Endotoxin testing

Endotoxins are inflammatory components of certain bacteria.

A product can be free from living bacteria yet still contain endotoxins.

Stability testing

Stability studies assess whether the peptide degrades over time under defined storage conditions.

WADA status

Semax is not specifically named in the publicly searchable summary of the World Anti-Doping Agency’s 2026 Prohibited List.

However, athletes should not assume that a non-approved neuroactive peptide is automatically permitted.

WADA categories may include unnamed substances based on:

• Similar chemical structure

• Similar biological effect

• Pharmacological category

• Non-approved substance rules

The official Prohibited List should be checked directly, and athletes should seek specialist anti-doping advice before using any experimental compound.

Common Semax myths

Myth: Semax is full-length ACTH.

Fact: Semax is a seven-amino-acid synthetic analogue containing a short ACTH-derived fragment.

Myth: Semax automatically increases cortisol.

Fact: It was developed to retain neuroactive properties without reproducing the full adrenal actions of ACTH, although comprehensive endocrine data remain limited.

Myth: Semax is proven to make healthy people smarter.

Fact: Evidence for broad cognitive enhancement in healthy humans is insufficient.

Myth: Increased BDNF guarantees brain repair.

Fact: BDNF signalling is complex, and experimental increases do not prove meaningful neurological recovery.

Myth: Semax reverses stroke damage.

Fact: It has been investigated as an adjunct in small studies, but it does not replace emergency stroke treatment.

Myth: Semax prevents dementia.

Fact: Prevention of human dementia has not been demonstrated.

Myth: Intranasal Semax goes directly to the brain.

Fact: Intranasal transport is variable, and precise human brain exposure has not been fully characterised.

Myth: Semax and Selank are the same.

Fact: They have different sequences, origins and principal research areas.

Myth: Semax has no side effects.

Fact: Its long-term safety and rare adverse effects remain insufficiently studied.

Myth: Research approval in one country means global approval.

Fact: Regulatory status differs between jurisdictions.

Frequently asked questions

Is Semax a peptide?

Yes. Semax is a synthetic peptide containing seven amino acids.

What is the Semax amino-acid sequence?

Its sequence is Met-Glu-His-Phe-Pro-Gly-Pro, abbreviated MEHFPGP.

What is Semax derived from?

It is derived from the ACTH 4–7 sequence with an added Pro-Gly-Pro tripeptide.

Is Semax the same as ACTH?

No. ACTH contains 39 amino acids, while Semax contains seven.

Does Semax increase cortisol?

It is not designed to reproduce the full adrenal effects of ACTH, but comprehensive endocrine-interaction data remain limited.

What is Semax researched for?

Its main research areas include cerebral ischaemia, neuroprotection, memory, attention and neurological recovery.

Is Semax a nootropic?

It is commonly described as a nootropic, but evidence for broad cognitive enhancement in healthy humans remains limited.

Does Semax improve memory?

Animal studies and limited human research suggest possible effects, but it has not been proven to improve everyday memory in healthy adults.

Does Semax improve focus?

Some research has examined attention, but it is not an approved treatment for attention disorders.

Does Semax treat ADHD?

No high-quality evidence establishes it as an ADHD treatment.

Does Semax increase BDNF?

Animal research has reported increases in BDNF-related expression and signalling.

Does increased BDNF mean Semax repairs the brain?

No. A molecular change does not automatically translate into clinical brain repair.

Is Semax neuroprotective?

It has shown neuroprotective effects in cell and animal models. Human clinical confirmation remains limited.

Does Semax help after stroke?

Small older studies reported favourable findings, but Semax is not part of standard UK stroke treatment.

Can Semax replace stroke medication?

No. Suspected stroke requires immediate emergency care.

Does Semax treat dementia?

No robust evidence establishes it as a dementia treatment.

Does Semax prevent Alzheimer’s disease?

Prevention has not been demonstrated.

Does Semax treat Parkinson’s disease?

There is insufficient clinical evidence.

Does Semax help concussion?

Robust human traumatic-brain-injury trials are lacking.

Does Semax affect dopamine?

Preclinical studies suggest it may influence dopamine signalling and stimulant-related dopamine release.

Does Semax affect serotonin?

Animal research suggests possible serotonergic modulation.

Is Semax an antidepressant?

It has not been established as a treatment for major depressive disorder.

Does Semax reduce anxiety?

Its anxiety evidence is weaker than Selank’s, and it is not an approved anxiety treatment.

Does Semax improve motivation?

This claim remains unproven.

Does Semax improve physical performance?

Controlled evidence supporting athletic-performance enhancement is lacking.

Is Semax a stimulant?

It is not classified as a conventional stimulant, although it may influence neurotransmitter systems associated with alertness and attention.

Does Semax cause insomnia?

Comprehensive adverse-event data are limited. Changes in alertness or sleep are possible in theory.

Does Semax cause headaches?

Headache is a plausible adverse effect, although reliable incidence estimates are unavailable.

Is Semax addictive?

A recognised dependence syndrome has not been established, but dedicated long-term studies are lacking.

Does Semax cause withdrawal?

A defined withdrawal syndrome has not been demonstrated.

How is Semax researched?

Intranasal administration is common in both animal and human studies.

Does Semax cross the blood-brain barrier?

Its precise transport and human brain exposure remain incompletely characterised.

How quickly does Semax work?

Some imaging changes have been observed within minutes, but this does not establish an immediate clinical benefit.

What is the half-life of Semax?

Comprehensive and widely validated human pharmacokinetic data are limited.

How long do Semax effects last?

Duration varies according to the outcome measured, and no universal clinically established duration exists.

Can Semax be combined with Selank?

Robust evidence establishing the safety or effectiveness of the combination is lacking.

Can Semax be combined with antidepressants?

Controlled interaction data are insufficient.

Can Semax be combined with ADHD medication?

Safety data are insufficient, and preclinical dopamine findings create potential interaction concerns.

Can Semax be combined with alcohol?

The interaction has not been adequately characterised.

Is Semax safe long term?

Long-term safety in healthy users has not been established.

Is Semax safe during pregnancy?

There is insufficient evidence to consider it safe during pregnancy or breastfeeding.

Is Semax safe for children?

Large modern paediatric safety trials are lacking.

Is Semax approved in the UK?

No.

Is Semax approved in Russia?

It has been described in scientific literature as developed and used as a medicine in Russia, but regulatory status differs from UK approval.

Is Semax prohibited by WADA?

It is not clearly named in the searchable summary, but broad WADA categories may apply. Athletes should obtain specialist guidance.

Is Semax the same as Selank?

No. They are chemically and biologically different peptides.

Which has more anxiety research, Semax or Selank?

Selank has been researched more specifically for anxiety.

Which has more neuroprotection research, Semax or Selank?

Semax has a larger literature focused on cerebral ischaemia and neuroprotection.

Can animal research prove Semax works in humans?

No. Controlled human trials are required to establish effectiveness.

Does a Russian clinical study prove Semax works?

It contributes evidence, but findings require assessment of trial design, sample size, controls and independent replication.

Does Semax permanently change the brain?

Permanent beneficial changes have not been established.

Semax research in context

What the evidence suggests

Experimental research suggests Semax may influence:

• BDNF and TrkB signalling

• NGF-related pathways

• Dopamine and serotonin transmission

• Inflammatory gene expression

• Oxidative-stress responses

• Mitochondrial stability

• Learning after experimental brain injury

• Functional connectivity between brain regions

Small human studies have also investigated cognitive effects and neurological recovery.

What remains uncertain

Researchers have not yet established:

• A single primary receptor

• Complete human pharmacokinetics

• Long-term safety

• Long-term effects in healthy users

• Effectiveness for ADHD

• Effectiveness for dementia

• Effectiveness after traumatic brain injury

• Comparative effectiveness against approved medicines

• Safety with psychiatric medication

• Reproductive safety

• Meaningful cognitive enhancement in healthy adults

Why further research is needed

Stronger evidence would require:

• Larger randomised controlled trials

• Placebo-controlled designs

• Independent international replication

• Transparent trial registration

• Modern stroke-treatment comparators

• Long-term follow-up

• Standardised cognitive testing

• Detailed adverse-event reporting

• Validated pharmacokinetic studies

Key takeaways

Semax is a synthetic seven-amino-acid peptide derived from part of the ACTH molecule.

Its sequence is:

Met-Glu-His-Phe-Pro-Gly-Pro

It was developed primarily for research involving:

• Neuroprotection

• Cerebral ischaemia

• Memory

• Attention

• Neurological recovery

Animal studies suggest Semax may influence:

• BDNF

• NGF

• Dopamine

• Serotonin

• Inflammatory signalling

• Gene expression

• Mitochondrial function

Small human studies have reported possible benefits in stroke and cognitive research, but the evidence does not meet the standard required to establish broad international clinical use.

Semax is not an authorised UK medicine.

It has not been proven to:

• Increase intelligence

• Prevent dementia

• Treat ADHD

• Reverse stroke damage

• Repair traumatic brain injury

• Produce reliable cognitive enhancement in healthy people

Its long-term safety, medicine interactions and effects in special populations remain insufficiently characterised.

Glossary

ACTH: Adrenocorticotropic hormone, a pituitary hormone involved in stimulating adrenal cortisol production.

Blood-brain barrier: A protective cellular system controlling movement of substances from the blood into the brain.

BDNF: Brain-derived neurotrophic factor, a protein involved in neuronal survival and plasticity.

Cerebral ischaemia: Reduced blood flow to brain tissue.

Default mode network: A network of brain regions associated with internally focused thought and memory.

Dopamine: A neurotransmitter involved in motivation, reward, attention and movement.

Excitotoxicity: Damage caused by excessive excitatory signalling in neurons.

Functional connectivity: Statistical coordination of activity between different brain regions.

Heptapeptide: A peptide containing seven amino acids.

Hypoxia: Reduced oxygen availability.

Intranasal: Administered through the nose.

Mitochondria: Cellular structures responsible for producing most ATP.

Neuroprotection: Preservation of nerve cells during injury or disease.

Neurotrophin: A protein supporting neuronal growth, survival and plasticity.

NGF: Nerve growth factor.

Nootropic: A broad term for a substance claimed to influence cognition.

Oxidative stress: An imbalance between reactive molecules and antioxidant defences.

Pro-Gly-Pro: A three-amino-acid sequence forming the C-terminal part of Semax.

Serotonin: A neurotransmitter involved in mood, sleep, appetite and pain.

TrkB: A receptor activated by BDNF.

Important notice

This article is provided for educational purposes only.

It is not intended to diagnose, treat or prevent disease or to replace advice from a qualified healthcare professional.

Semax is not an authorised medicine in the United Kingdom.

Although laboratory studies, animal experiments and small human studies have investigated its effects on neuroprotection, cerebral ischaemia, cognition and brain signalling, the evidence remains limited.

Claims that Semax prevents dementia, reverses stroke damage, treats ADHD or reliably enhances cognition in healthy people extend beyond what has been established through robust clinical research.